Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma
Sign Up to like & getrecommendations! Published in 2019 at "JAMA Dermatology"
DOI: 10.1001/jamadermatol.2018.3958
Abstract: Importance A phase 2 trial comparing talimogene laherparepvec plus ipilimumab vs ipilimumab monotherapy in patients with advanced unresectable melanoma found no differential benefit in progression-free survival (PFS) but noted objective response rates (ORRs) of 38.8%… read more here.
Keywords: talimogene laherparepvec; life; laherparepvec plus; plus ipilimumab ... See more keywords